[ANIP] ANI Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 622.64 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 63.26 Change: 0.76 (1.22%)

chart ANIP

Refresh chart

Description: ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. The company manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products; and Lithobid lithium carbonate extended release tablets. Its targeted areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company offers generic products, including Esterified Estrogen with Methyltestosterone tablets for use in treating vasomotor symptoms of menopause; Fluvoxamine Maleate to treat obsessions and compulsions in patients with obsessive-compulsive disorder; Hydrocortisone Enema for the treatment of ulcerative colitis; Metoclopramide syrup for treating heartburn symptoms with gastroesophageal reflux disease; and Opium Tincture to treat severe diarrhea by slowing the movement of the intestines, as well as branded p

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding11.49 M EPS0.7 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 182.82% Sales Growth - Q/Q-10.64% P/E64.69
P/E To EPS Growth P/S9.75 P/BV4.3 Price/Cash Per Share
Price/Free Cash Flow29.77 ROA11.19% ROE20.56% ROI
Current Ratio22.37 Quick Ratio21.19 Long Term Debt/Equity Debt Ratio0.06
Gross Margin81.84% Operating Margin40.83% Net Profit Margin46.59% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities20 K Cash From Investing Activities-4.61 M Cash From Operating Activities1.12 M Gross Profit16.05 M
Net Profit4.37 M Operating Profit9.57 M Total Assets265.99 M Total Current Assets202.99 M
Total Current Liabilities9.07 M Total Debt112.17 M Total Liabilities121.25 M Total Revenue18.8 M
Technical Data
High 52 week74.56 Low 52 week43.45 Last close58.68 Last change0.46%
RSI57.53 Average true range2.07 Beta0.82 Volume99.67 K
Simple moving average 20 days-0.77% Simple moving average 50 days-2.07% Simple moving average 200 days0.85%
Performance Data
Performance Week-3.23% Performance Month1.73% Performance Quart-13.66% Performance Half-2.27%
Performance Year10.49% Performance Year-to-date-8.95% Volatility daily1.87% Volatility weekly4.19%
Volatility monthly8.58% Volatility yearly29.73% Relative Volume340.74% Average Volume118.68 K
New High New Low

News

2019-02-28 02:31:58 | Edited Transcript of ANIP earnings conference call or presentation 27-Feb-19 3:30pm GMT

2019-02-28 01:08:08 | ANI Pharmaceuticals ANIP Q4 2018 Earnings Conference Call Transcript

2019-02-27 08:30:00 | ANI Pharmaceuticals Reports Record Full Year and Fourth Quarter 2018 Results and Provides 2019 Guidance

2019-02-21 11:30:29 | Should We Be Cautious About ANI Pharmaceuticals, Inc.’s NASDAQ:ANIP ROE Of 0.2%?

2019-02-20 08:30:00 | ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Year-to-Date 2018 Financial Results

2019-02-13 07:40:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Amkor Technology, U.S. Silica, Steven Madden, Rowan Companies, SunOpta, and ANI Pharmaceuticals — New Research Emphasizes Economic Growth

2019-01-09 11:48:32 | How Much is ANI Pharmaceuticals, Inc.’s NASDAQ:ANIP CEO Getting Paid?

2019-01-01 09:21:00 | 3 Under-the-Radar Value Stocks to Buy in 2019

2018-12-27 16:30:00 | ANI Pharmaceuticals Secures Refinancing for Convertible Debt Due December 2019 and Enters Amended Five-Year $265 Million Senior Secured Credit Facility

2018-12-18 01:26:14 | Hedge Funds Are Crazy About ANI Pharmaceuticals Inc ANIP

2018-12-07 08:00:00 | ANI Pharmaceuticals Enters into Separate Privately Negotiated Agreements with Certain Holders of its Convertible Notes

2018-11-30 07:51:00 | 3 Top Small-Cap Stocks to Buy Right Now

2018-11-27 13:45:54 | What You Must Know About ANI Pharmaceuticals Inc’s NASDAQ:ANIP Financial Strength

2018-11-20 09:30:02 | Is ANI Pharmaceuticals a Great Stock for Value Investors?

2018-11-15 09:15:00 | ANI Pharmaceuticals, Inc. Ranked Number 366 Fastest Growing Company in North America on Deloitte's 2018 Technology Fast 500™

2018-11-12 07:25:00 | Research Report Identifies Canopy Growth, MSG Networks, ANI Pharmaceuticals, Mistras Group, Rowan Companies, and Chemours with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-11-06 17:21:59 | Edited Transcript of ANIP earnings conference call or presentation 6-Nov-18 3:30pm GMT

2018-11-06 13:17:37 | ANI Pharmaceuticals Inc ANIP Q3 2018 Earnings Conference Call Transcript

2018-11-06 10:15:03 | ANI Pharmaceuticals ANIP Q3 Earnings and Revenues Surpass Estimates

2018-11-06 09:12:29 | ANI: 3Q Earnings Snapshot

2018-11-06 08:30:00 | ANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2018 Results and Reaffirms Guidance

2018-10-30 08:30:00 | ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2018 Financial Results

2018-10-18 09:00:00 | Analysis: Positioning to Benefit within Clovis Oncology, Destination Maternity, MSG Networks, Lindblad Expeditions, NetScout, and ANI Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2018-10-16 09:00:00 | ANI Announces Launch of Authorized Generic of Brethine®

2018-10-04 08:30:00 | ANI Pharmaceuticals Announces Launch of Authorized Generic of Atacand HCT® Tablets

2018-09-27 08:30:00 | ANI Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

2018-09-25 11:50:14 | ANI Pharmaceuticals Inc NASDAQ:ANIP Is Trading At A 47.84% Discount

2018-09-25 10:46:56 | New Product Launches to Drive Ani Pharmaceuticals’ 2018 Revenue

2018-08-27 07:45:00 | Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences — Renewed Outlook, Key Drivers of Growth

2018-08-20 11:45:06 | Edited Transcript of ANIP earnings conference call or presentation 7-Aug-18 2:30pm GMT

2018-08-08 13:00:00 | ANI Pharmaceuticals to Present at New Time at the Canaccord Genuity 38th Annual Growth Conference

2018-08-07 10:05:02 | ANI Pharmaceuticals ANIP Lags Q2 Earnings and Revenue Estimates

2018-08-07 09:00:31 | ANI: 2Q Earnings Snapshot

2018-08-07 08:30:00 | ANI Pharmaceuticals, Inc. to Host Earnings Call

2018-08-07 08:30:00 | ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance

2018-08-06 08:30:00 | ANI Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference

2018-08-01 08:30:00 | ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2018 Financial Results

2018-07-06 14:36:06 | Dermira DERM Gains 5% in a Week, Post-Qbrexa Approval

2018-07-06 07:47:11 | Zacks Industry Outlook Highlights: Amgen, ANI and Illumina

2018-07-04 08:28:12 | Juniper Inks Deal to be Acquired by Catalent, Shares Up

2018-07-03 15:27:07 | Alkermes' Aristada Initio Approved by FDA for Schizophrenia

2018-07-03 15:22:07 | Roche's Breast Cancer Study Meets Co-Primary Endpoint

2018-06-29 14:54:06 | Celgene's Luspatercept Meets Primary Endpoint in the Study

2018-06-29 09:08:01 | Keryx KERX Inks Merger Deal With Akebia, Shares Fall

2018-06-28 17:31:09 | Medicines Company's Inclisiran Studies to Continue Unmodified

2018-06-28 10:51:02 | Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review

2018-06-27 18:39:10 | Infinity and Arcus Ink Deal for Two Triple Combo Studies

2018-06-27 10:32:02 | Puma Biotechnology's Shares Rise on Positive CHMP Trend Vote

2018-06-27 08:00:00 | ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP

2018-06-26 11:09:03 | Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies